medroxyprogesterone acetate has been researched along with Cardiovascular Stroke in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.88) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 12 (70.59) | 29.6817 |
| 2010's | 3 (17.65) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, J; Liu, X; Yang, D; Yuan, Z | 1 |
| Arias-Loza, PA; Bayer, B; Dienesch, C; Ertl, G; Frantz, S; Hu, K; Pelzer, T; Wu, R | 1 |
| Barnhart, KT; Chen, TJ; Chen, YC; Hwang, WT; Liu, Z; Su, IH; Su, TP; Yang, YX | 1 |
| Anderson, GL; Beresford, SA; Howard, BV; Jackson, RD; Johnson, KC; Kooperberg, C; Kotchen, JM; LaCroix, AZ; Ockene, J; Prentice, RL; Rossouw, JE; Stefanick, ML | 1 |
| Derry, PS | 1 |
| Breckwoldt, M | 1 |
| Assaf, AR; Black, HR; Crouse, JR; Cushman, M; Detrano, R; Heckbert, SR; Hsia, J; Johnson, KC; Lasser, NL; Manson, JE; Rossouw, JE; Stein, E; Strickland, OL; Trevisan, M; Wong, ND | 1 |
| Heinemann, V; Parhofer, K | 1 |
| Shapiro, S | 1 |
| Booth, EA; Lucchesi, BR | 1 |
| de Bruijn, HW; Hindriks, FR; Kremer, J | 1 |
| Barrett-Connor, E; Hulley, SB; Knopp, RH; Levy, RI; Lin, F; Shlipak, MG; Simon, JA; Vittinghoff, E | 1 |
| Colditz, GA; Grodstein, F; Manson, JE; Speizer, FE; Stampfer, MJ; Willett, WC | 1 |
| Bittner, V; Blumenthal, RS; Fong, J; Harris, F; Herrington, DM; Hunninghake, D; Levy, R; Lin, F; Schrott, HG; Vittinghoff, E | 1 |
| Bittner, V; Blumenthal, R; Davidson, M; Grady, D; Herd, A; Herrington, D; Hlatky, M; Hsia, J; Hulley, S; Khan, S; Newby, LK; Vittinghoff, E; Waters, D; Wenger, N | 1 |
1 review(s) available for medroxyprogesterone acetate and Cardiovascular Stroke
| Article | Year |
|---|---|
Effect of hormone replacement therapy on cardiovascular outcomes: a meta-analysis of randomized controlled trials.
Topics: Cardiovascular Diseases; Estrogens; Female; Hormone Replacement Therapy; Humans; Medroxyprogesterone Acetate; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2013 |
7 trial(s) available for medroxyprogesterone acetate and Cardiovascular Stroke
| Article | Year |
|---|---|
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.
Topics: Aged; Breast Neoplasms; Clinical Trials Data Monitoring Committees; Colorectal Neoplasms; Coronary Disease; Endometrial Neoplasms; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Fractures, Bone; Humans; Medroxyprogesterone Acetate; Middle Aged; Myocardial Infarction; Postmenopause; Progesterone Congeners; Proportional Hazards Models; Pulmonary Embolism; Risk; Stroke; Survival Analysis; Thrombosis; Treatment Outcome | 2002 |
Time trends in the HERS secondary prevention trial: much ado about nothing?
Topics: Adult; Aged; Death, Sudden, Cardiac; Drug Combinations; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Myocardial Infarction; Progesterone Congeners; Randomized Controlled Trials as Topic; Treatment Outcome | 2002 |
Estrogen plus progestin and the risk of coronary heart disease.
Topics: Aged; Case-Control Studies; Coronary Disease; Double-Blind Method; Drug Combinations; Estrogens, Conjugated (USP); Female; Follow-Up Studies; Heart Diseases; Hormone Replacement Therapy; Humans; Medroxyprogesterone Acetate; Middle Aged; Myocardial Infarction; Postmenopause; Progesterone Congeners; Proportional Hazards Models; Risk Factors; Treatment Outcome | 2003 |
[Risk and benefits of hormone replacement therapy by postmenopausal women. WHI-Study].
Topics: Aged; Breast Neoplasms; Colorectal Neoplasms; Coronary Disease; Endometrial Neoplasms; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Fractures, Bone; Hormone Replacement Therapy; Humans; Incidence; Medroxyprogesterone Acetate; Middle Aged; Myocardial Infarction; Postmenopause; Progesterone Congeners; Proportional Hazards Models; Pulmonary Embolism; Risk Assessment; Stroke; Survival Analysis; Thrombosis; Treatment Outcome; United States; Women's Health | 2003 |
Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause.
Topics: Aged; Coronary Disease; Estrogens, Conjugated (USP); Female; Follow-Up Studies; Hormone Replacement Therapy; Humans; Lipoprotein(a); Medroxyprogesterone Acetate; Middle Aged; Myocardial Infarction; Postmenopause; Proportional Hazards Models; Recurrence; Risk Factors | 2000 |
Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS).
Topics: Aged; Cardiovascular Diseases; Coronary Disease; Drug Interactions; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Medroxyprogesterone Acetate; Myocardial Infarction; Postmenopause; Thromboembolism | 2002 |
Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).
Topics: Aged; Aspirin; Coronary Disease; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Medroxyprogesterone Acetate; Myocardial Infarction; Postmenopause; Risk Factors; Survival Analysis; Treatment Outcome | 2002 |
9 other study(ies) available for medroxyprogesterone acetate and Cardiovascular Stroke
| Article | Year |
|---|---|
Medroxyprogesterone acetate aggravates oxidative stress and left ventricular dysfunction in rats with chronic myocardial infarction.
Topics: Analysis of Variance; Animals; Blood Pressure; Cardiomegaly; Chronic Disease; Electrocardiography; Estradiol; Female; Heart Rate; Histocytochemistry; Medroxyprogesterone Acetate; Myocardial Infarction; NADPH Oxidases; Ovariectomy; Oxidative Stress; Rats; Rats, Wistar; Reactive Oxygen Species; Ventricular Dysfunction, Left; Ventricular Remodeling | 2011 |
Risks and benefits of menopausal hormone therapy in postmenopausal Chinese women.
Topics: Aged; Asian People; Breast Neoplasms; Cardiovascular Diseases; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Myocardial Infarction; Postmenopause; Risk Assessment; Taiwan | 2012 |
Postmenopausal hormone therapy offers no protection against heart attacks.
Topics: Aged; Controlled Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Drug Combinations; Estrogens; Estrogens, Conjugated (USP); Female; Follow-Up Studies; Gallbladder Diseases; Hormone Replacement Therapy; Humans; Medroxyprogesterone Acetate; Middle Aged; Myocardial Infarction; Placebos; Postmenopause; Progesterone Congeners; Progestins; Randomized Controlled Trials as Topic; Risk Factors; Thrombosis; Time Factors | 2002 |
[Hormone replacement therapy in menopause].
Topics: Aged; Breast Neoplasms; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Menopause; Middle Aged; Myocardial Infarction | 2003 |
Risk of cardiovascular disease in relation to the use of combined postmenopausal hormone therapy: detection bias and resolution of discrepant findings in two Women's Health Initiative studies.
Topics: Aged; Cardiovascular Diseases; Confounding Factors, Epidemiologic; Coronary Disease; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Myocardial Infarction; Postmenopause; Randomized Controlled Trials as Topic; Risk Assessment; Stroke; Thromboembolism; Time Factors; Women's Health | 2006 |
Medroxyprogesterone acetate prevents the cardioprotective and anti-inflammatory effects of 17beta-estradiol in an in vivo model of myocardial ischemia and reperfusion.
Topics: Animals; Antineoplastic Agents, Hormonal; Blood Pressure; Disease Models, Animal; Drug Interactions; Estradiol; Heart; Heart Rate; Male; Malondialdehyde; Medroxyprogesterone Acetate; Myocardial Infarction; Myocardial Reperfusion Injury; Rabbits; Reperfusion Injury; Troponin I | 2007 |
[Injectable contraceptive, DMPA, serum HDL cholesterol and heart infarct].
Topics: Adult; Cholesterol; Cholesterol, HDL; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Intrauterine Devices; Lipoproteins, HDL; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Myocardial Infarction; Risk | 1981 |
Estrogen and heart attack.
Topics: Estrogens; Female; Hormone Replacement Therapy; Humans; Medroxyprogesterone Acetate; Myocardial Infarction | 1998 |
A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease.
Topics: Adult; Aged; Cardiovascular Diseases; Coronary Disease; Drug Administration Schedule; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Myocardial Infarction; Postmenopause; Prospective Studies; Regression Analysis; Risk Factors; Stroke | 2000 |